Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Alterations in the p53 pathway and prognosis in advanced ovarian cancer: a multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865).
Green JA, Berns EM, Coens C, van Luijk I, Thompson-Hehir J, van Diest P, Verheijen RH, van de Vijver M, van Dam P, Kenter GG, Tjalma W, Ewing PC, Teodorovic I, Vergote I, van der Burg ME; EORTC Gynaecological Cancer Group. Green JA, et al. Among authors: van luijk i, van dam p, van diest p, van de vijver m, van der burg me. Eur J Cancer. 2006 Oct;42(15):2539-48. doi: 10.1016/j.ejca.2006.06.015. Epub 2006 Sep 11. Eur J Cancer. 2006. PMID: 16965910 Clinical Trial.
A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group.
van Diest PJ, van Dam P, Henzen-Logmans SC, Berns E, van der Burg ME, Green J, Vergote I. van Diest PJ, et al. Among authors: van dam p, van der burg me. J Clin Pathol. 1997 Oct;50(10):801-4. doi: 10.1136/jcp.50.10.801. J Clin Pathol. 1997. PMID: 9462258 Free PMC article. No abstract available.
Phase II study of fotemustine in patients with advanced ovarian carcinoma. A trial of the EORTC Gynecological Cancer Group.
Aapro MS, van Wijk FH, van der Burg ME, ten Bokkel Huinink W, Vergote I, Guastalla JP, Rosso R, Kobierska A, Beex LV, Namer M, Splinter TE, Vermorken JB. Aapro MS, et al. Among authors: van wijk fh, van der burg me. Eur J Cancer. 2003 May;39(8):1141-3. doi: 10.1016/s0959-8049(03)00198-9. Eur J Cancer. 2003. PMID: 12736114 Clinical Trial.
Randomized phase III trial of bleomycin, vindesine, mitomycin-C, and cisplatin (BEMP) versus cisplatin (P) in disseminated squamous-cell carcinoma of the uterine cervix: an EORTC Gynecological Cancer Cooperative Group study.
Vermorken JB, Zanetta G, De Oliveira CF, van der Burg ME, Lacave AJ, Teodorovic I, Boes GH, Colombo N. Vermorken JB, et al. Among authors: van der burg me. Ann Oncol. 2001 Jul;12(7):967-74. doi: 10.1023/a:1011165115426. Ann Oncol. 2001. PMID: 11521804 Free article. Clinical Trial.
Serum proteomic patterns for ovarian cancer monitoring.
Helleman J, van der Vlies D, Jansen MP, Luider TM, van der Burg ME, Stoter G, Berns EM. Helleman J, et al. Among authors: van der vlies d, van der burg me. Int J Gynecol Cancer. 2008 Sep-Oct;18(5):985-95. doi: 10.1111/j.1525-1438.2007.01139.x. Epub 2007 Nov 20. Int J Gynecol Cancer. 2008. PMID: 18028381
151 results